Skip to main content

Advertisement

Table 1 Patient characteristics

From: A Serological Biomarker of Versican Degradation is Associated with Mortality Following Acute Exacerbations of Idiopathic Interstitial Pneumonia

  Total IIP population IPF subpopulation Paired IIP
  S AE p value S AE p value S AE p value
n 29 68   11 28   28 28  
Age (mean SD) 69 (8) 71 (7) 0.206 67 (8) 71 (7) 0.150 68.3 (7.6) 68.3 (7.6) NA
Female gender (n %) 6 (21%) 12 (18%) 0.726 0 (0%) 0 (0%) NA 6 (21%) 6 (21%) NA
Smokers (n %)
 Current 0 (0%) 1 (1%) 0.514 0 (0%) 0 (0%) NA 0 (0%) 0 (0%) NA
 Ex 23 (79%) 50 (74%) 0.548 9 (82%) 23 (82%) 0.981 22 (79%) 22 (79%)
 Never 6 (21%) 17 (25%) 0.649 2 (18%) 5 (18%) 0.981 6 (21%) 6 (21%)
FVC %pred (mean SD) 79 (27) 56 (19) < 0.0001 73 (13) 55 (16) 0.0014 77 (26) 59 (24) < 0.0001
VC (%pred), mean SD 78.7 (26.0) 54.6 (18.9) < 0.0001 72.7 (13.5) 53.6 (16.0) 0.0023 76 (25) 57 (23) < 0.0001
Time from IIP diagnosis to AE admission, months (median IQR)   12 (3–38)    29 (11–40)    24 (8–38)  
Treatment duration from AE admission, days (median IQR)   8 (3–14)    7 (2–12)    8 (4–16)  
Non-survivors at 100 days after AE admission (n %)   37 (54%)    13 (46%)    15 (54%)  
Time to death after AE admission, days (median IQR)   15 (6–35)    15 (4–43)    17 (10–30)  
  1. Patient characteristics at time of stability (S) and acute exacerbation (AE) of idiopathic interstitial pneumonia (IIP) for the total population, and subpopulations of patients with idiopathic pulmonary fibrosis (IPF) or patients with paired samples (IPF n = 11). S and AE were compared for each population using Mann-Whitney test, Chi squared test, or Wilcoxon test as appropriate